KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill (2016 - 2025)

Teva Pharmaceutical Industries' Goodwill history spans 17 years, with the latest figure at $16.0 billion for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill rose 5.63% year-over-year to $16.0 billion, compared with a TTM value of $16.0 billion through Dec 2025, up 5.63%, and an annual FY2025 reading of $16.0 billion, up 5.63% over the prior year.
  • Goodwill for Q4 2025 was $16.0 billion at Teva Pharmaceutical Industries, roughly flat from $15.9 billion in the prior quarter.
  • The five-year high for Goodwill was $20.4 billion in Q2 2021, with the low at $266.0 million in Q2 2022.
  • Average Goodwill over 5 years is $16.6 billion, with a median of $17.1 billion recorded in 2023.
  • Year-over-year, Goodwill plummeted 98.7% in 2022 and then surged 6335.34% in 2023.
  • Tracing TEVA's Goodwill over 5 years: stood at $17.6 billion in 2021, then decreased by 2.59% to $17.2 billion in 2022, then changed by 0.0% to $17.2 billion in 2023, then dropped by 11.82% to $15.1 billion in 2024, then rose by 5.63% to $16.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Goodwill are $16.0 billion (Q4 2025), $15.9 billion (Q3 2025), and $15.9 billion (Q2 2025).